Sector News

AstraZeneca secures $486m from US for Covid-19 antibody

October 17, 2020
Life sciences

AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment.

AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment.

The company signed the deal with the US Biomedical Advanced Research and Development Authority (BARDA). It intends to supply up to 100,000 doses of the therapeutic beginning towards the end of this year.

As part of a separate deal, the US can purchase up to one million additional doses next year.

AZD7442 is a cocktail of two LAABs obtained from convalescent patients after Covid-19 infection. The LAABs could potentially minimise the risk of resistance developed by SARS-CoV-2.

Engineered with half-life extension and decreased Fc receptor binding, the LAABs have the potential to provide six to 12 months of protection against the disease with a single administration.

AstraZeneca secured the licence for the LAAB combination, discovered by Vanderbilt University Medical Center, in June.

In the coming weeks, AZD7442 will progress into two Phase III trials in a total of over 6,000 subjects enrolled at sites across the US and other countries.

A trial of around 5,000 participants will assess the safety and efficacy of AZD7442 to prevent Covid-19 for up to 12 months. Another trial will analyse post-exposure prophylaxis and pre-emptive treatment in around 1,100 volunteers.

The company also intends to conduct additional trials of the therapeutic in around 4,000 Covid-19 patients.

AstraZeneca CEO Pascal Soriot said: “This agreement with the US Government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections.”

The company received more than $1bn from the BARDA in May to develop, manufacture and deliver a Covid-19 vaccine developed by the University of Oxford.

Later, in August, the European Commission (EC) signed a deal with AstraZeneca for the supply of the Covid-19 vaccine candidate to the European Union Member States.

By Pharmaceutical-technology.com

Source: Pharmaceutical-technology.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach